Literature DB >> 11888915

Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.

William R Wilson1, Susan M Pullen, Alison Hogg, Nuala A Helsby, Kevin O Hicks, William A Denny.   

Abstract

The efficacy of cancer gene therapy depends critically on "bystander effects" by which genetic modification of tumor cells results in killing of unmodified cells in the local microenvironment. In gene-dependent enzyme-prodrug therapy, expression of a prodrug-activating suicide gene is used to generate a cytotoxic metabolite that diffuses to nontransduced cells. The objective of this study was to develop a physiologically relevant tissue culture model for quantifying bystander effects and to validate the model using as an example the activation of dinitrobenzamide prodrugs (e.g., CB 1954) by Escherichia coli aerobic nitroreductase (NTR). Bystander effects were measured in three-dimensional multilayer cocultures of NTR+ and NTR- cells by determining clonogenic survival curves for both cell types using V79, Skov3, or WiDr as parental cell lines. Bystander killing by CB 1954 was much more efficient in multilayers than monolayers at equivalent cell:medium ratios, whereas the chloromustard analogue of CB 1954 showed even greater efficiency. For a series of dinitrobenzamides, bystander killing in multilayers showed a positive correlation with prodrug lipophilicity and also correlated with the bystander effect in mixed tumor xenografts grown from the same NTR+ and NTR- WiDr cell lines (r(2) = 0.84; P < 0.001). The multilayer model identified a bromomustard prodrug (SN 24927) with superior therapeutic activity to CB 1954 that provided curative activity against WiDr tumors comprising 1:1 mixtures of NTR+ and NTR- cells. This study demonstrates the utility of the multilayer tissue culture model for quantifying and optimizing bystander effects in tumors and identifies a new lead prodrug for NTR gene-dependent enzyme-prodrug therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888915

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit.

Authors:  Dean C Singleton; Alexandra M Mowday; Chris P Guise; Sophie P Syddall; Sally Y Bai; Dan Li; Amir Ashoorzadeh; Jeff B Smaill; William R Wilson; Adam V Patterson
Journal:  Cancer Gene Ther       Date:  2021-11-26       Impact factor: 5.854

2.  Cloning, expression, and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 nasopharyngeal carcinoma cell line.

Authors:  Xinmin Nie; Bicheng Zhang; Xiaoling Li; Juanjuan Xiang; Bingyi Xiao; Jian Ma; Ming Zhou; Shiguo Zhu; Hongbin Lu; Rong Gui; Shourong Shen; Guiyuan Li
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-18       Impact factor: 4.553

3.  Transgenic mice expressing nitroreductase gene under the control of the podocin promoter: a new murine model of inductible glomerular injury.

Authors:  Guillaume Macary; Jérome Rossert; Patrick Bruneval; Chantal Mandet; Marie-France Bélair; Pascal Houillier; Jean-Paul Duong Van Huyen
Journal:  Virchows Arch       Date:  2009-10-06       Impact factor: 4.064

4.  Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.

Authors:  Cho Rong Hong; Sunali Y Mehta; H D Sarath Liyanage; Sarah P McManaway; Ho H Lee; Jagdish K Jaiswal; Gib Bogle; Moana Tercel; Frederik B Pruijn; William R Wilson; Kevin O Hicks
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-10       Impact factor: 3.333

5.  Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.

Authors:  Alexandra M Mowday; Ludwig J Dubois; Aleksandra M Kubiak; Jasmine V E Chan-Hyams; Christopher P Guise; Amir Ashoorzadeh; Philippe Lambin; David F Ackerley; Jeff B Smaill; Nigel P Minton; Jan Theys; Adam V Patterson
Journal:  Cancer Gene Ther       Date:  2021-02-08       Impact factor: 5.987

6.  The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.

Authors:  Laura K Green; Mathew A Storey; Elsie M Williams; Adam V Patterson; Jeff B Smaill; Janine N Copp; David F Ackerley
Journal:  Cancers (Basel)       Date:  2013-08-08       Impact factor: 6.639

7.  Establishment of a transgenic zebrafish line for superficial skin ablation and functional validation of apoptosis modulators in vivo.

Authors:  Chi-Fang Chen; Che-Yu Chu; Te-Hao Chen; Shyh-Jye Lee; Chia-Ning Shen; Chung-Der Hsiao
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

8.  Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.

Authors:  Laura K Green; Sophie P Syddall; Kendall M Carlin; Glenn D Bell; Christopher P Guise; Alexandra M Mowday; Michael P Hay; Jeffrey B Smaill; Adam V Patterson; David F Ackerley
Journal:  Mol Cancer       Date:  2013-06-10       Impact factor: 27.401

9.  Evaluating baculovirus as a vector for human prostate cancer gene therapy.

Authors:  Stephanie L Swift; Guillermo C Rivera; Vincent Dussupt; Regina M Leadley; Lucy C Hudson; Corrina Ma de Ridder; Robert Kraaij; Julie E Burns; Norman J Maitland; Lindsay J Georgopoulos
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.

Authors:  S O Vass; D Jarrom; W R Wilson; E I Hyde; P F Searle
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.